SIGNIFICANCE OF COPEPTIN IN DIAGNOSTICS OF MYOCARDIAL INFARCTION
https://doi.org/10.15829/1560-4071-2017-11-93-97
Abstract
In the review, studies results are presented on the significance of laboratory marker copeptin in diagnostics of myocardial infarction (MI) and further prognosis evaluation. Copeptin (surrogate marker of vasopressin) represents the severity of endogenic neurohormonal stress and significantly increases in blood during the first hour of MI course, declining at tenth hour from onset. Negative values of copeptin and troponin T make it with high grade of credibility to rule out MI. Grade of copeptin increase correlates with the size of myocardium necrosis focus and further prognosis of the disease: sudden death risk and progression of chronic heart failure.
References
1. Campbell R. Myocardial infarction: International guidelines. M.: 1997; 87 p. (InRuss.) Kэмпбелл Р. Международное руководство по инфаркту миокарда. М.: 1997; 87 c.
2. Сhambless L, Keil U, Dobson A, et al. Population versus clinical view of case fatality from acute coronary heart disease: results from WHO MONICA 1985-1990. Circulation 1997; 96: 3849-59.
3. Kesov PG, Shalaev SV. Risk factors, clinical manifestations, and especially the treatment of acute coronary syndrome from the standpoint of the gender perspective. Meducal science and education of Ural 2015; 16 (2): 164-8. (In Russ.) Кесов П.Г., Шалаев С.В. Факторы риска, клинические проявления и особенности терапии острого коронарного синдрома с позиции гендерных аспектов. Медицинская наука и образование Урала 2015; 16 (2): 164-8.
4. Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. Circulation 2012; 126 (16): 2020-35.
5. Thygesen K, Mair J, Giannitsis E, et al. How to Use High — Sensititity Cardiac Troponins in Acute Cardiac Care. Eur Heart J 2012; 33 (18): 2252-7.
6. Jobs A, Thiele H. ESC guidelines 2015: NonSTelevation acute coronary Syndrome. Herz 2015; 40 (8): 1027-33.
7. Khan SQ. C-Terminal Provasopressin (Copepnin) as a Novel and Prognostic Marker in Acute Myocardial Infarction. LAMP Study. Circulation 2007; 115: 2103-10.
8. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: 1129-38.
9. Kokorin VA, Luyson VA, Shaiduyk OY. Increased activity neurohumoral systems of myocardial infarction patients: prognostic importance. Scientific records sevics of Medicine. Pharmacy 2011; 10 (105): 37-43. (In Russ.) Кокорин В.А., Люсов В.А., Шайдюк О.Ю. Прогностическая значимость повышения активности нейрогуморальных систем у больных инфарктом миокарда. Научные ведомости. Серия Медицина. Фармация. 2011; 10 (105): 37-43.
10. Muller B, Morgenthaler N, Stolz D, et al. Circulating levels of copeptin, a novel biomarkers, in lower respiratory tract infections. Eur J of Clinical Invest 2007; 37 (2): 145-52.
11. Morgenthaler N, Muller B, Struck J, et al. Copepnin a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007; 28 (2): 219-26.
12. Katan M, Fluri F, Morgenthaler N, et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann of Neurology 2009; 66 (6): 799-808.
13. Sang G, Du J-M, Chen YY, et al. Plasma copeptin levels are associated with prognosis of severe acute pancreatitis. Peptides 2014; 51: 4-8.
14. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54 (1): 60-8.
15. Gu YL, Voors AA, Zijlstra F, et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin Res Cardiol 2011; 100 (12): 1069-76.
16. Ananth V, Beig JR, Tramboo N, et al. Does plasma copeptin level at admission predict final infarct size in ST — elevation myocardial infarction. International J of Cardiology 2016; 219: 326-30.
17. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol 2010; 55 (19): 2096-106.
18. Afzali D, Erren M, Pavenstadt H-J, et al. Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin Research in Cardiology 2013; 102: 755-63.
19. Folli Ch, Consonni D, Spessot M, et al. Diagnostic rolle of copeptin in patients presenting with chest pain in the emergency room. Eur J of Internal Medicine 2013; 24 (2): 189-93.
20. El Sayed ZH, Mahmoud HA, El Shall LY, et al. Impact of copeptin on diagnosis of acute coronary syndrome. Egyptian J of Medical Human Genetics 2014; 15 (3): 241-7.
21. Liorens P, Sanchez M, Herrero P, et al. The utility of copeptin in the emergency department for non — ST — elevation myocardial infarction rapid rule out: COPED-MIRRO study. Eur J Emerg Med 2014; 21 (3): 220-9.
22. Hillinger P, Twerenbold R, Jaeger C, et al. Optimizing early rule-out strategies for acute myocardial infarction: utility of 1-hour copeptin. Clinical Chemistry 2015; 61 (12): 1466-74.
23. Mockel M, Searle J, Hamm Ch, et al. Earle discharge using single cadiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study. Eur Heart J 2014; 36 (6): 369-76.
24. Khan SQ, Dhillon OS, O`Brien RJ, et al. C-Terminal Provasopressin (Copeptin a Novel and Prognostic Marker in Acute Myocardial Infarction. Leicester Acute Myocardial Infarction Peptide (LAMP) Study. Circulation 2007; 115: 2103-10.
25. Narayan H, Dhillon OS, Quinn PA, et al. C-terminal provasopressin (copeptin) as a prognostic marker after acute nonST — elevation myocardial infarction: leicester acute myocardial infarction peptide II (LAMP II) study. Clinical Science 2011; 121 (2): 79-89.
26. Potocki M, Reichlin T, Thalmann S, et al. Diagnostic and prognostic impact of copeptin and high-sensitivity cardiac troponin T in patients with pre-existing coronary artery disease and suspected acute myocardial infarction. Heart 2012; 98 (7): 558-65.
27. O`Malley RG, Bonaca MP, Scirica BM, et al. Prognostic performance of multiple biomarkers in patients with non — ST — segment elevation acute coronary syndrome: analysis from the MERLIN — TIMI 36 trial. J of the American College of Cardiology 2014: 63 (16): 1644-53.
28. Searle J, Slagman A, Stockburger M, et al. Use of copeptin in emergency patients with cardiac chief complaints. Eur Heart J 2015; 4 (5) 393-402.
29. Morawiec B, Kawecki D, Lam Ho, et al. COPeptin for diagnosis and prediction in acute coronary syndrome study: desing and objectives. Postery Kardiol Interwencyjnej 2016; 12 (4): 360-3.
30. Vargas KG, Kassem M, Mueller Ch, et al. Copeptin for the early rule-out of non — ST — elevation myocardial infarction. International J of Cardiology 2016; 223: 797-804.
Supplementary files
|
1. Сопроводительное письмо | |
| Subject | инфаркт миокарда; диагностика; прогноз; копептин | |
| Type | Исследовательские инструменты | |
Download
(54KB)
|
Indexing metadata ▾ | |
|
|
2. Титульный лист | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(8KB)
|
Indexing metadata ▾ | |
|
|
3. Подписи | |
| Subject | ||
| Type | Исследовательские инструменты | |
Download
(66KB)
|
Indexing metadata ▾ | |
Review
For citations:
Kremneva L.V. SIGNIFICANCE OF COPEPTIN IN DIAGNOSTICS OF MYOCARDIAL INFARCTION. Russian Journal of Cardiology. 2017;(11):93-97. (In Russ.) https://doi.org/10.15829/1560-4071-2017-11-93-97
Views:
1268
Email this article 